Abstract

Purpose The purpose of the study is to assess longitudinal changes in general and disease-specific health-related quality-of-life (HRQOL) indices after intensity-modulated radiotherapy (IMRT) monotherapy for patients with localized prostate cancer (PCA).Methods Between 2006 and 2010, 91 patients with localized PCA underwent IMRT monotherapy and were enrolled into this prospective study. At baseline, and at 3, 6, 12, and 24 months after IMRT, the general and prostate-specific HRQOL were estimated using physical (PCS) and mental component summaries (MCS) calculated using the Medical Outcomes Study 8-Item Short Form Health Survey and Expanded Prostate Cancer Index Composite (EPIC).ResultsFor 2 years, there were no significant changes in EPIC scores in all subscales of urinary domain, hormonal function, and bother. Bowel and sexual function scores decreased after IMRT and did not return to those at baseline (p = 0.006 and < 0.001, respectively). PCS began to decrease at 3 months after IMRT and then returned to the baseline score at 24 months. In contrast, the MCS score began to significantly increase after IMRT, and thereafter the score remained constant until 24 months (p < 0.001). On multivariate logistic regression analysis, urinary (p = 0.003) and sexual functions (p = 0.0005) at baseline were identified as significant predictors of EPIC urinary irritative/obstructive score and sexual function at 24 months after IMRT.ConclusionUrinary function, including irritative/obstruction symptoms and hormonal function, was not affected by IMRT. However, bowel and sexual function decreased after IMRT. These findings will provide important information for PCA patients considering IMRT.

Highlights

  • External-beam radiation therapy (EBRT) and radical prostatectomy (RP) have been the gold standard treatments forQual Life Res (2014) 23:1641–1650 clinically localized prostate cancer (PCA), and they have resulted in an excellent disease-free survival outcome for patients [1, 2]

  • To the best of our knowledge, this is the first time that longitudinal changes in health-related quality-of-life (HRQOL) after intensity-modulated radiotherapy (IMRT) monotherapy have been evaluated in patients with clinically localized PCA using Expanded Prostate Cancer Index Composite (EPIC), which measures urinary irritative symptoms and hormonal function as well as urinary incontinence and bowel function

  • Namiki et al [6] reported that the urinary function and bother scores were similar after IMRT and conformal radiation therapy (CRT) and did not change for 5 years after treatment

Read more

Summary

Introduction

External-beam radiation therapy (EBRT) and radical prostatectomy (RP) have been the gold standard treatments forQual Life Res (2014) 23:1641–1650 clinically localized prostate cancer (PCA), and they have resulted in an excellent disease-free survival outcome for patients [1, 2]. There have been a few large studies using the EPIC for patients who underwent EBRT alone [13, 14]; some patients received three-dimensional conformal radiotherapy. Patients are naturally concerned with possible changes in various functions (for example, urinary and bowel functions) following treatment For this reason, it is very important for patients who are considering IMRT monotherapy to have information about the longitudinal changes in QOL after treatment. We prospectively evaluated the longitudinal changes in general and disease-specific HRQOL after IMRT monotherapy for patients with localized PCA using the EPIC and the Medical Outcomes Study 8-Item Short Form Health Survey (SF-8)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call